Cepheid weakness a buying opportunity, says RW Baird Baird recommends using potential HBDC-related weakness a s buying opportunity. The firm believes consensus estimates may not appropriately reflect the near-term HBDC accounting dynamics and is waiting on the guidance from the company's earnings conference call following its report on Thursday. Shares are Outperform rated with a $45 price target.
Cepheid upgraded to Buy from Hold at Craig-Hallum Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.